Tatva Chintan Pharma Intrinsic Value
Tatva Chintan Pharma (TATVA) median intrinsic value is ₹344.04 from 9 valuation models (range ₹340–₹573), vs current price ₹1146.80 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Browse TATVA annual financials for revenue, profit, balance sheet and cash flow data.
TATVA Valuation Methods Summary — DCF, Graham Number & P/E
Tatva Chintan Pharma intrinsic value across 9 models vs current price ₹1146.80 — upside/downside and value range per method. For current market price and key ratios, visit Tatva Chintan Pharma screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹344.04 | ₹275.23 - ₹412.85 | -70.0% | EPS: ₹17.64, Sector P/E: 12x |
| Book Value Method | asset | ₹340.00 | ₹306.00 - ₹374.00 | -70.4% | Book Value/Share: ₹340.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹344.04 | ₹309.64 - ₹378.44 | -70.0% | Revenue/Share: ₹233.04, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹458.72 | ₹412.85 - ₹504.59 | -60.0% | EBITDA: ₹112.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹458.72 | ₹366.98 - ₹550.46 | -60.0% | CF Growth: 5.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹344.04 | ₹309.64 - ₹378.44 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹344.04 | ₹309.64 - ₹378.44 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹573.40 | ₹516.06 - ₹630.74 | -50.0% | ROE: 5.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹367.35 | ₹330.62 - ₹404.09 | -68.0% | EPS: ₹17.64, BVPS: ₹340.00 |
TATVA Intrinsic Value vs Market Price — All Valuation Models
Tatva Chintan Pharma fair value range ₹340–₹573 vs current market price ₹1146.80 across 9 valuation models. Also explore Tatva Chintan Pharma share price performance to track price trends across different timeframes.
TATVA Intrinsic Value Analysis — Undervalued or Overvalued?
Tatva Chintan Pharma median intrinsic value ₹344.04, current price ₹1146.80 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of TATVA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Tatva Chintan Pharma (TATVA) is ₹344.04 (median value). With the current market price of ₹1146.80, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹340.00 to ₹573.40, indicating ₹340.00 - ₹573.40.
Is TATVA undervalued or overvalued?
Based on our multi-method analysis, Tatva Chintan Pharma (TATVA) appears to be trading above calculated value by approximately 70.0%.
TATVA Financial Health — Key Ratios vs Industry Benchmarks
Tatva Chintan Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 38.89 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.53x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
TATVA Cash Flow Quality — Operating & Free Cash Flow
Tatva Chintan Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹25 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹98 Cr | ₹38 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹28 Cr | ₹-23 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹20 Cr | ₹-79 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹20 Cr | ₹10 Cr | Positive Free Cash Flow | 7/10 |